articleTop 1% cited

Pharmacokinetics of Intravitreal Bevacizumab (Avastin)

Ophthalmology · 2007 · Vol. 114(5) · pp. 855–859

Sophie J. Bakri✉(Mayo Clinic)Melissa R. Snyder(Mayo Clinic)Joel M. Reid(Mayo Clinic)José S. Pulido(Mayo Clinic in Florida)Ravinder J. Singh(Mayo Clinic)

View via DOI Publisher page

Retinal Diseases and Treatments Retinal and Macular Surgery Vascular Malformations Diagnosis and TreatmentBevacizumabMedicinePharmacokineticsOphthalmologyAqueous humorPharmacologyChemotherapySurgery

MeSH terms

BevacizumabAnimalsAntibodies, MonoclonalAqueous HumorHalf-LifeMaleRabbitsTissue DistributionVitreous BodyAngiogenesis InhibitorsVascular Endothelial Growth Factor AAntibodies, Monoclonal, Humanized

Funding

Research to Prevent Blindness

Citations

675

FWCI

54.81

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Prospective study of intravitreal triamcinolone acetonide versus bevacizumab with or without laser for macular edema secondary to retinal vein occlusion

International Journal of Medical Ophthalmology · 2019 · 0 citations

Predicted biological activity of intravitreal VEGF Trap

British Journal of Ophthalmology · 2008 · 371 citations

References

Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration

Investigative Ophthalmology & Visual Science · 2005 · 502 citations

Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy

Ophthalmology · 2006 · 798 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.